Indeed, the efficacy of this strategy has been hinted by some elegant clinical studies, which showed that better immunological and clinical responses were obtained in melanoma or myeloma patients that had received CD4+ T cell-containing donor cells following preconditioning chemotherapy [129, 131]. The gene discussed is CD4; the disease is melanoma.